Article
Behavioral Sciences
Aliakbar Mariki, Zahra Barzin, Majid Fasihi Harandi, Kimia Karbasi Ravari, Mahboubeh Davoodi, Seyed Mohammad Mousavi, Soheila Rezakhani, Masoud Nazeri, Mohammad Shabani
Summary: This study found that antigen B from hydatid cyst fluid could reduce the levels of anti-inflammatory cytokines in rats with experimental autoimmune encephalomyelitis (EAE)-induced multiple sclerosis (MS) and increase nerve conduction velocity. The results showed that antigen B modulated the immune system and reduced the inflammatory component of the EAE MS animal model, leading to a decrease in symptoms at the behavioral and electrophysiological level. Antigen B could be used as a potential therapeutic agent to regulate the immune system in MS patients.
BRAIN AND BEHAVIOR
(2023)
Review
Immunology
Krista D. DiSano, Francesca Gilli, Andrew R. Pachner
Summary: Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, with B cells emerging as central players in the immune pathogenesis of the disease. Memory B cells (Bmem) are considered key B cell phenotypes in MS due to their antigen-experience, increased lifespan, and rapid response to stimulation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Alana L. Keller, Daniel W. Sherbenou, Peter A. Forsberg, Tomer M. Mark
Summary: Multiple myeloma is an incurable hematologic malignancy characterized by initial treatment response followed by resistance development. Novel immunotherapeutics utilizing patients' own T cells, such as CAR T cell therapy and bispecific antibodies, have displayed impressive efficacy in clinical trials for myeloma patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Bibiana Quirant-Sanchez, Maria Jose Mansilla, Juan Navarro-Barriuso, Silvia Presas-Rodriguez, Aina Teniente-Serra, Federico Fondelli, Cristina Ramo-Tello, Eva Martinez-Caceres
Summary: Autologous antigen-specific therapies based on tolerogenic dendritic cells (tolDC) offer the possibility to treat autoimmune diseases, and combining tolDC with an immunomodulatory treatment like interferon beta (IFN-beta) can enhance the suppressive ability of tolDC and induce immune profile shifts. In a mouse model of experimental autoimmune encephalomyelitis (EAE), a combined therapy based on antigen-specific VitD3-tolDC and IFN-beta showed promising results in ameliorating the disease course compared to monotherapy.
Review
Immunology
Andreas Lutterotti, Helen Hayward-Koennecke, Mireia Sospedra, Roland Martin
Summary: Antigen-specific tolerance induction offers personalized treatment for multiple sclerosis by targeting antigens and core pathomechanisms, requiring distinct clinical development approaches. Key aspects include patient selection, outcome measures, demonstrating mechanisms of action, and positioning in the spectrum of MS treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jinrong Yang, Weilin Zhou, Dan Li, Ting Niu, Wei Wang
Summary: This article summarizes the application and research progress of BCMA-targeting CAR T cell therapy in the treatment of multiple myeloma, as well as measures to improve efficacy and safety.
Article
Oncology
Ajay K. Nooka, Cesar Rodriguez, Maria Victoria Mateos, Salomon Manier, Katherine Chastain, Arnob Banerjee, Rachel Kobos, Keqin Qi, Raluca Verona, Margaret Doyle, Thomas G. Martin, Niels W. C. J. van de Donk
Summary: Infections were examined in patients with relapsed/refractory multiple myeloma treated with teclistamab, and the study found that they were at increased risk of infection. Various types of infections were reported, including COVID-19 and respiratory infections. Prompt intervention and appropriate screening, prophylaxis, and management of infections are important for these patients.
Review
Immunology
Rongzeng Liu, Shushu Du, Lili Zhao, Sahil Jain, Kritika Sahay, Albert Rizvanov, Vera Lezhnyova, Timur Khaibullin, Ekaterina Martynova, Svetlana Khaiboullina, Manoj Baranwal
Summary: Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by destruction of the myelin sheath. Immune mechanisms, particularly abnormal lymphocyte activity, play a key role in the pathogenesis of multiple sclerosis. This review summarizes the abnormal function and count of lymphocytes and their contributions to the mechanisms of multiple sclerosis. Additionally, novel therapies aimed at correcting the aberrant function or count of these lymphocytes are discussed.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Jamie K. Wong, Jerry Lin, Nathan J. Kung, Alexandra L. Tse, Serena J. E. Shimshak, Anna K. Roselle, Francesca M. Cali, Jessie Huang, Joseph M. Beaty, Taylor M. Shue, Saud A. Sadiq
Summary: Multiple sclerosis can present as relapsing-remitting or progressive forms. It is unclear whether these forms represent the same disease or distinct entities with similar pathological features. This study provides evidence that primary progressive multiple sclerosis is characterized by a unique capacity of cerebrospinal fluid (CSF) to induce motor disability and spinal cord pathology, which can be attenuated by removing immunoglobulin G from the CSF. Injection of recombinant antibodies derived from primary progressive multiple sclerosis CSF reproduces the pathology, suggesting an antibody-mediated and distinct pathogenic mechanism for this form of the disease. These findings have important implications for developing targeted therapies for primary progressive multiple sclerosis patients.
Review
Medicine, Research & Experimental
Shirin Teymouri Nobari, Jafar Nouri Nojadeh, Mehdi Talebi
Summary: BCMA is a transmembrane glycoprotein highly expressed on plasma cells of MM patients and the normal population. It is used as a biomarker for MM. Proteins related to BCMA play a crucial role in plasma cell survival and MM progression. Various antibody and CAR-T cell therapies have been used for anti-MM treatment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Taewoong Choi, Yubin Kang
Summary: Although treatment outcomes for multiple myeloma patients have greatly improved in the past two decades, the disease remains incurable. New immunotherapies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy, have emerged to treat multiple myeloma. This article provides a comprehensive review of the clinical efficacy, safety, and potential resistance mechanisms of current myeloma CAR-T therapies, with a focus on B Cell Maturation Antigen (BCMA) as the most successful target. The article also discusses novel strategies to enhance the effectiveness of myeloma CAR-T therapy.
PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Immunology
Maria Teresa Martin Monreal, Bjarke E. Hansen, Pernille F. Iversen, Christian Enevold, Niels Odum, Finn Sellebjerg, Peter Hojrup, Marina Rode von Essen, Claus H. Nielsen
Summary: The research suggests that citrullination, a post-translational modification, may play a role in the development of multiple sclerosis (MS). The autoimmune response to myelin basic protein (MBP) is enhanced when it is hypercitrullinated in MS patients. In addition, citMBP binds more effectively to HLA-DR15, which is associated with MS, compared to native MBP. These findings point to the importance of citrullination in breaching tolerance to MBP and maintaining the autoimmune response in MS patients.
JOURNAL OF AUTOIMMUNITY
(2023)
Article
Medicine, Research & Experimental
Zhao-Lan Hu, Cong Luo, Plinio Reinaldo Hurtado, Hui Li, Shuang Wang, Bo Hu, Jun-Mei Xu, Yang Liu, Shi-Qing Feng, Ernesto Hurtado-Perez, Kang Chen, Xin-Fu Zhou, Chang-Qi Li, Ru-Ping Dai
Summary: The study found that proBDNF from immune cells promotes the immunopathogenesis of multiple sclerosis (MS). Monoclonal Ab-proB may be a promising therapeutic agent for treating MS.
Review
Biotechnology & Applied Microbiology
Tereza Gabelic, Barbara Barun, Ivan Adamec, Magdalena Krbot Skoric, Mario Habek
Summary: Traditionally, the management of active relapsing remitting MS involved continuous treatment with disease modifying therapy, while newer approaches include short-term therapy or the use of monoclonal antibodies. The introduction of monoclonal antibodies has revolutionized MS treatment, but the choice of DMT remains a challenge for patients and neurologists.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Review
Multidisciplinary Sciences
Andre Eduardo de Almeida Franzoi, Fernanda Subtil de Moraes Machado, Washigton Luiz Gomes de Medeiros Junior, Isabelle Pastor Bandeira, Wesley Nogueira Brandao, Marcus Vinicius Magno Goncalves
Summary: miRNAs play crucial roles in MS by regulating gene expression in various cells. NTZ treatment modifies gene expression and miRNA levels in B cells, indicating a potential for specific miRNAs to serve as markers of therapeutic response in MS patients. Understanding the complex interaction between miRNAs, gene expression in B cells, and therapeutic response is important for MS treatment.
Article
Biochemistry & Molecular Biology
Winde Jorissen, Tim Vanmierlo, Inez Wens, Veerle Somers, Bart Van Wijmeersch, Jeroen F. Bogie, Alan T. Remaley, Bert O. Eijnde, Jerome J. A. Hendriks
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Dermatology
Jolien Robijns, Sandrine Censabella, Stefan Claes, Luc Pannekoeke, Lore Busse, Dora Colson, Iris Kaminski, Paul Bulens, Annelies Maes, Leen Noe, Marc Brosens, An Timmermans, Ivo Lambrichts, Veerle Somers, Jeroen Mebis
LASERS IN SURGERY AND MEDICINE
(2018)
Article
Multidisciplinary Sciences
G. Montes Diaz, J. Fraussen, B. Van Wijmeersch, R. Hupperts, V. Somers
SCIENTIFIC REPORTS
(2018)
Letter
Oncology
Jolien Robijns, Sandrine Censabella, Stefan Claes, Luc Pannekoeke, Lore Busse, Dora Colson, Iris Kaminski, Victoria Broux, Joy Lodewijckx, Sofie Puts, Paul Bulens, Annelies Maes, Leen Noe, Marc Brosens, An Timmermans, Ivo Lambrichts, Veerle Somers, Jeroen Mebis
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2019)
Article
Immunology
Suzan Wetzels, Tim Vanmierlo, Jean L. J. M. Scheijen, Jack van Horssen, Sandra Amor, Veerle Somers, Casper G. Schalkwijk, Jerome J. A. Hendriks, Kristiaan Wouters
FRONTIERS IN IMMUNOLOGY
(2019)
Review
Immunology
Rut Mazon-Cabrera, Patrick Vandormael, Veerle Somers
FRONTIERS IN IMMUNOLOGY
(2019)
Article
Immunology
Judith Fraussen, Susanna Marquez, Kazushiro Takata, Lien Beckers, Gwendoline Montes Diaz, Chrysoula Zografou, Bart Van Wijmeersch, Luisa M. Villar, Kevin C. O'Connor, Steven H. Kleinstein, Veerle Somers
JOURNAL OF IMMUNOLOGY
(2019)
Article
Rheumatology
Dana Quaden, Patrick Vandormael, Pieter Ruytinx, Piet Geusens, Kristoff Corten, Johan Vanhoof, Jori Liesenborgs, Frank van Reeth, Anouk Agten, Frank Vandenabeele, Kurt de Vlam, Veerle Somers
ARTHRITIS & RHEUMATOLOGY
(2020)
Article
Chemistry, Analytical
Seppe Bormans, Gilles Oudebrouckx, Patrick Vandormael, Thijs Vandenryt, Patrick Wagner, Veerle Somers, Ronald Thoelen
Summary: The study introduces a novel approach for monitoring cell proliferation by continuously measuring changes in thermal properties at the sensor interface. The method accurately measures variations in the number of cells and shows potential for high-throughput monitoring of cell proliferation.
Article
Cell Biology
Bram Van den Broek, Isabel Pintelon, Ibrahim Hamad, Sofie Kessels, Mansour Haidar, Niels Hellings, Jerome J. A. Hendriks, Markus Kleinewietfeld, Bert Brone, Vincent Timmerman, Jean-Pierre Timmermans, Veerle Somers, Luc Michiels, Joy Irobi
JOURNAL OF EXTRACELLULAR VESICLES
(2020)
Article
Medicine, General & Internal
Loes Linsen, Kimberly Vanhees, Evi Vanoppen, Kim Ulenaers, Suzanne Driessens, Joris Penders, Veerle Somers, Piet Stinissen, Jean-Luc Rummens
FRONTIERS IN MEDICINE
(2019)
Meeting Abstract
Clinical Neurology
L. Beckers, G. Montes Diaz, L. M. Villar, B. Van Wijmeersch, V. Somers, J. Fraussen
MULTIPLE SCLEROSIS JOURNAL
(2019)
Meeting Abstract
Rheumatology
Dana Quaden, Patrick Vandormael, Piet Geusens, Johan Vanhoof, Kurt de Vlam, Veerle Somers
ANNALS OF THE RHEUMATIC DISEASES
(2019)
Meeting Abstract
Rheumatology
Silke Loyens, Patrick Vandormael, Liesbeth De Winter, Veerle Stouten, Piet Geusens, Patrick Verschueren, Veerle Somers
ANNALS OF THE RHEUMATIC DISEASES
(2019)